Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astria Therapeutics Inc (ATXS)

Astria Therapeutics Inc (ATXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 731,259
  • Shares Outstanding, K 57,085
  • Annual Sales, $ 0 K
  • Annual Income, $ -94,260 K
  • EBIT $ -137 M
  • EBITDA $ -137 M
  • 60-Month Beta 0.01
  • Price/Sales 1,052.54
  • Price/Cash Flow N/A
  • Price/Book 5.13

Options Overview Details

View History
  • Implied Volatility 244.54% (-62.04%)
  • Historical Volatility 17.58%
  • IV Percentile 80%
  • IV Rank 36.78%
  • IV High 590.44% on 04/11/25
  • IV Low 43.30% on 10/14/25
  • Expected Move (DTE 35) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 142
  • Volume Avg (30-Day) 19
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 1,108
  • Open Int (30-Day) 1,117
  • Expected Range 12.45 to 12.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.54
  • Number of Estimates 2
  • High Estimate -0.52
  • Low Estimate -0.55
  • Prior Year -0.44
  • Growth Rate Est. (year over year) -22.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.44 +0.04%
on 01/16/26
13.28 -6.36%
on 01/07/26
-0.43 (-3.34%)
since 12/16/25
3-Month
11.83 +5.16%
on 10/17/25
13.29 -6.40%
on 12/04/25
+0.35 (+2.89%)
since 10/16/25
52-Week
3.56 +249.44%
on 04/09/25
13.29 -6.40%
on 12/04/25
+4.69 (+60.52%)
since 01/16/25

Most Recent Stories

More News
Halper Sadeh LLC Encourages CSGS, JHG, CWAN, ATXS Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

ATXS : 12.45 (-2.81%)
CSGS : 79.53 (+0.06%)
JHG : 47.92 (+0.06%)
CWAN : 24.25 (+0.25%)
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

NEW YORK and NEW ORLEANS , Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating the...

ATXS : 12.45 (-2.81%)
BCRX : 6.61 (-7.81%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR

NEW YORK , Dec. 19, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

ATXS : 12.45 (-2.81%)
SEMR : 11.90 (+0.17%)
MBCN : 35.16 (+1.24%)
FMNB : 13.55 (+0.15%)
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ATXS : 12.45 (-2.81%)
TCBX : 38.42 (-0.32%)
RNA : 72.54 (-0.08%)
FSUN : 39.02 (-0.91%)
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN

NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

ATXS : 12.45 (-2.81%)
TCBX : 38.42 (-0.32%)
RNA : 72.54 (-0.08%)
FSUN : 39.02 (-0.91%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-SPNS, PCH, ATXS, and RYN

NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

ATXS : 12.45 (-2.81%)
SPNS : 43.45 (+0.02%)
PCH : 45.18 (+1.57%)
RYN : 24.55 (+1.82%)
Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ATXS : 12.45 (-2.81%)
MRUS : 90.00 (-7.14%)
HSII : 59.01 (+0.07%)
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

-- BioCryst’s Acquisition of Astria Expected to Close in the First Quarter of 2026 -- -- Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned...

ATXS : 12.45 (-2.81%)
BCRX : 6.61 (-7.81%)
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

-- Final ALPHA-STAR Phase 1b/2 Results from the Full-Enrollment Population (n=29) Remain Highly Consistent with Prior Results from the Target-Enrollment Population (n=16), Demonstrating Strong Efficacy,...

ATXS : 12.45 (-2.81%)
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final...

ATXS : 12.45 (-2.81%)

Business Summary

Astria Therapeutics is a biopharmaceutical company which focuses on therapies to treat allergic and immunological diseases. The company's program include STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Astria Therapeutics,...

See More

Key Turning Points

3rd Resistance Point 13.37
2nd Resistance Point 13.11
1st Resistance Point 12.96
Last Price 12.45
1st Support Level 12.55
2nd Support Level 12.30
3rd Support Level 12.15

See More

52-Week High 13.29
Last Price 12.45
Fibonacci 61.8% 9.57
Fibonacci 50% 8.43
Fibonacci 38.2% 7.28
52-Week Low 3.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar